玛伐凯泰在梗阻性与非梗阻性肥厚型心肌病中的安全性和疗效:随机对照试验荟萃分析
该荟萃分析纳入5项随机对照试验共1083例成人肥厚型心肌病患者,评估玛伐凯泰的疗效与安全性。梗阻性患者中玛伐凯泰显著改善NYHA分级和KCCQ-CSS并大幅降低LVOT压差,非梗阻性患者无功能获益且LVEF<50%风险显著升高。结论支持表型导向的精准治疗,非梗阻性患者需谨慎使用并加强超声监测。
要点
- 梗阻性肥厚型心肌病患者使用玛伐凯泰可显著改善症状和左室流出道梗阻,安全性总体可接受。
- 非梗阻性肥厚型心肌病患者无功能获益,且左室射血分数降至50%以下的风险显著升高。
- 两种表型患者生物标志物(NT-proBNP、hs-cTnI)均显著下降,提示药物具有生物学活性。
核心结论
- 玛伐凯泰在梗阻性肥厚型心肌病中有效改善症状和梗阻且安全性令人安心,在非梗阻性患者中虽驱动生化和结构重塑却无有意义的症状获益,并可能显著增加临床相关收缩功能障碍风险。
研究设计与样本
- 检索PubMed、Scopus和Web of Science至2025年10月的随机对照试验,共纳入5项RCT、1083例患者(梗阻性444例,非梗阻性639例),采用随机效应模型合并数据并按表型分层。
主要发现
- 梗阻性患者中玛伐凯泰显著改善NYHA分级(OR 4.94;95%CI 3.25至7.49)和KCCQ-CSS(MD 8.99),并大幅降低LVOT压差。
- 非梗阻性患者中LVEF降至<50%的风险显著升高(OR 14.35;95%CI 5.92至34.77),但基于有限事件需谨慎解读。
- 梗阻性患者中LVEF降至<50%的风险未显著升高(OR 2.08;95%CI 0.79至5.48)。
- 非梗阻性患者无功能获益,KCCQ-CSS提示可能恶化(MD -0.70,95%CI -1.26至-0.14)。
- 两种表型患者NT-proBNP和hs-cTnI均显著下降,证实生物学活性。
关键数值与推荐
- 梗阻性肥厚型心肌病:NYHA改善OR 4.94(95%CI 3.25至7.49),KCCQ-CSS改善MD 8.99。
- 非梗阻性肥厚型心肌病:LVEF<50%风险OR 14.35(95%CI 5.92至34.77),KCCQ-CSS变化MD -0.70(95%CI -1.26至-0.14)。
- 梗阻性肥厚型心肌病:LVEF<50%风险OR 2.08(95%CI 0.79至5.48)。
临床怎么用
- 梗阻性肥厚型心肌病患者可考虑使用玛伐凯泰以改善症状和左室流出道梗阻。
- 非梗阻性肥厚型心肌病患者应谨慎使用玛伐凯泰,需严格超声心动图监测左室射血分数。
- 非梗阻性疾病的超说明书使用应持审慎态度,基于表型选择治疗。
局限性
- 非梗阻性患者中LVEF<50%风险的估计基于有限事件数,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mavacamten, a selective cardiac myosin inhibitor, is a therapeutic option for hypertrophic cardiomyopathy (HCM). Its impact on exercise capacity, health-related quality of life and left ventricular outflow tract (LVOT) obstruction, alongside differential phenotype effects, remains incompletely characterised. This meta-analysis evaluates mavacamten's efficacy and safety in adults with HCM. METHODS: We searched PubMed, Scopus and Web of Science through October 2025 for randomised controlled trials (RCTs) assessing mavacamten in HCM. Outcomes included New York Heart Association (NYHA) class, Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS), peak VO₂, LVOT gradient, cardiac structure, biomarkers and adverse events. Data were pooled using random-effects models, stratified by phenotype (obstructive HCM (oHCM) vs non-obstructive HCM (nHCM)). Risk of bias was assessed via Cochrane risk-of-bias tool for randomised trials (RoB-2), alongside trial sequential analysis and Grading of Recommendations, Assessment, Development and Evaluation (GRADE). RESULTS: Five RCTs (1083 patients; 444 oHCM, 639 nHCM) were included. In oHCM, mavacamten markedly improved NYHA class (OR 4.94; 95% CI 3.25 to 7.49) and KCCQ-CSS (MD 8.99), with substantial LVOT gradient reductions. Serious adverse events did not increase overall in either phenotype. The risk of left ventricular ejection fraction declining <50% was considerably elevated in nHCM (OR 14.35; 95% CI 5.92 to 34.77)-though based on limited events, requiring cautious interpretation-but not elevated in oHCM (OR 2.08; 95% CI 0.79 to 5.48). Additionally, nHCM patients showed no functional benefit and a suggestive KCCQ-CSS worsening (MD -0.70, 95% CI -1.26 to -0.14). Biomarkers (NT-proBNP, hs-cTnI) decreased substantially across both phenotypes, confirming biological activity. CONCLUSION: Mavacamten appears effective in oHCM, improving symptoms and obstruction with a reassuring safety profile. In nHCM, it drives biochemical and structural remodelling without conferring meaningful symptomatic benefit, while potentially posing a considerably elevated risk of clinically relevant systolic dysfunction. These findings support phenotype-guided precision therapy, urging stringent echocardiographic surveillance and caution regarding off-label use in non-obstructive disease. PROSPERO REGISTRATION NUMBER: CRD420251176149.
引用
- Alazzam AY, Almajdoubeh OA, Barakat A, et al. Safety and efficacy of mavacamten in obstructive versus non-obstructive hypertrophic cardiomyopathy: a meta-analysis of randomised controlled trials. Heart. 2026. PMID: 42259617. doi:10.1136/heartjnl-2025-327651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。